Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Frontiers in immunology·2026
Same author

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.

European journal of neurology·2026
Same author

Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.

Annals of clinical and translational neurology·2026
Same author

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Annals of neurology·2026
Same author

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants.

Annals of clinical and translational neurology·2026
Same journal

Proprioceptive Stimuli as a Trigger for Leucine-Rich Glioma-Inactivated-1 (LGI1) IgG Associated Autoimmune Seizures, a Case Report.

The Neurohospitalist·2026
Same journal

Electronic Health Record-Based Estimates of Acute Disseminated Encephalomyelitis Epidemiology in a Large Healthcare Network, 2000-2025.

The Neurohospitalist·2026
Same journal

Substance Use and Toxicology Screening in Young Adults With Acute Ischemic Stroke.

The Neurohospitalist·2026
Same journal

Images in Clinical Neurology: A Case of Poorly Differentiated Chondrosarcoma.

The Neurohospitalist·2026
Same journal

Clinical Problem Solving: A 35-Year-Old Pregnant Woman With Subacute Encephalopathy.

The Neurohospitalist·2026
Same journal

Corrigendum to "A Unique Case and Presentation of Anti-GAD Paraneoplastic Encephalitis".

The Neurohospitalist·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K

2014 multiple sclerosis therapeutic update.

Bruce A C Cree1

  • 1UCSF MS Center, Department of Neurology, San Francisco, CA, USA.

The Neurohospitalist
|April 8, 2014
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis therapies are rapidly advancing, with new drugs targeting inflammation and progressive disease. Future research aims to promote remyelination and neuroprotection for multiple sclerosis (MS) patients.

Keywords:
clinical trialsprogressive multiple sclerosisrandomized controlled trialsrelapsing multiple sclerosistherapeutics

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K

Related Experiment Videos

Last Updated: May 1, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K

Area of Science:

  • Neurology
  • Immunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Current disease-modifying therapies (DMTs) primarily target neuroinflammation.
  • There is a need for treatments addressing neuroprotection and remyelination in MS.

Purpose of the Study:

  • To review recent advances in multiple sclerosis disease-modifying therapies.
  • To discuss emerging treatments for relapsing and progressive forms of MS.
  • To outline future research directions in MS, including remyelination and neuroprotection.

Main Methods:

  • Review of recent scientific literature and clinical trial data on MS therapies.
  • Analysis of novel anti-neuroinflammatory medications and their mechanisms.
  • Examination of ongoing research into treatments for progressive MS and vitamin D supplementation.

Main Results:

  • Significant progress in developing novel anti-inflammatory drugs for MS.
  • Emerging therapeutic strategies for progressive MS, including targeted agents.
  • Ongoing trials investigating vitamin D's role in relapsing MS.

Conclusions:

  • The therapeutic landscape for MS is rapidly evolving with new drug approvals.
  • Future MS research should prioritize strategies for remyelination and neuronal protection.
  • A multi-faceted approach combining anti-inflammatory, remyelinating, and neuroprotective strategies is essential for MS management.